Pharmacokinetics of IV Formulation

Key facts

Sponsor

F2G Biotech GmbH

Principal Investigator

Litza McKenzie, MD

Quotient Clinical

Intervention

F901318(drug)

Eligibility

18-55 years · All sexes

Timeline

2017 – 2017

Collaborators

Quotient Clinical

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT07238114
  Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
  Universitaire Ziekenhuizen KU Leuven
• RECRUITINGPHASE2NCT06794554
  Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options
  Mundipharma Research Limited
• RECRUITINGNCT07313527
  PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value
  University Hospital, Strasbourg, France
• ACTIVE NOT RECRUITINGNCT06583512
  Treatment Duration of IPA
  Peking University People's Hospital
• RECRUITINGNCT06885905
  Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being
  Imperial College London
• RECRUITINGNANCT06440915
  Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
  Shanghai Children's Medical Center
• RECRUITINGPHASE3NCT06447402
  A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis
  Post Graduate Institute of Medical Education and Research, Chandigarh
• RECRUITINGPHASE2NCT05653193
  Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
  Manchester University NHS Foundation Trust

See all trials for Aspergillosis →